Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MIF | P14174 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30252319 | 0.80 | MAOA (0.52) | MAOAMAOBCYP2A6CES1NOS3 | |
| SCHEMBL268687 | 0.75 | CYP2A6 (0.45) | MAOAMAOBCYP2A6CES1NOS3 | |
| SCHEMBL57446 | 0.73 | MAOA (0.46) | MAOAMAOBCYP2A6CES1PDPK1 | |
| SCHEMBL11144928 | 0.73 | CES1 (0.73) | MAOAMAOBCYP2A6CES1PDPK1 | |
| SCHEMBL31430380 | 0.71 | TSHR (0.71) | MAOAMAOBCYP2A6CES1NOS3 | |
| SCHEMBL3103992 | 0.71 | CYP2A6 (0.68) | MAOAMAOBCYP2A6CES1NOS3 | |
| SCHEMBL568779 | 0.71 | TSHR (0.71) | MAOAMAOBCYP2A6CES1NOS3 | |
| SCHEMBL30505637 | 0.71 | CYP2A6 (0.68) | MAOAMAOBCYP2A6CES1NOS3 | |
| SCHEMBL44545 | 0.71 | MAOA (1.00) | MAOAMAOBCYP2A6CES1PDPK1 | |
| SCHEMBL18607288 | 0.71 | MAOA (0.91) | MAOAMAOBCYP2A6CES1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-03 | — | — | US | claimed |
| EP-2140868-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy | Eisai R&D Management Co., Ltd. (JP) | 2010-01-06 | — | — | EP | claimed |
| EP-2138177-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments | Eisai R&D Management Co., Ltd. (JP) | 2009-12-30 | — | — | EP | claimed |
| EP-2133078-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments | Eisai R&D Management Co., Ltd. (JP) | 2009-12-16 | — | — | EP | claimed |
| EP-2130538-A1 | Use of a cholinesterase inhibitor for the delaying the onset of Alzheimer's disease | Eisai R&D Management Co., Ltd. (JP) | 2009-12-09 | — | — | EP | claimed |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2008-12-18 | — | — | US | claimed |
| EP-1729761-A4 | CADASIL TREATMENT WITH CHOLINESTERASE INHIBITORS | EISAI CO LTD (JP) | 2008-09-03 | — | — | EP | claimed |
| EP-1764101-A1 | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments | Eisai R&D Management Co., Ltd. (JP) | 2007-03-21 | — | — | EP | claimed |
| EP-1729761-A1 | CADASIL TREATMENT WITH CHOLINESTERASE INHIBITORS | Eisai Co., Ltd. (JP) | 2006-12-13 | — | — | EP | claimed |
| EP-1311272-B1 | NOVEL METHODS USING CHOLINESTERASE INHIBITORS | EISAI CO LTD (JP) | 2006-11-22 | — | — | EP | claimed |
| EP-1311272-A1 | NOVEL METHODS USING CHOLINESTERASE INHIBITORS | Eisai Co., Ltd. (JP) | 2003-05-21 | — | — | EP | claimed |
| EP-1311272-A4 | NOVEL METHODS USING CHOLINESTERASE INHIBITORS | EISAI CO LTD (JP) | 2003-05-21 | — | — | EP | claimed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | claimed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| WO-2001066114-A1 | NOVEL METHODS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2001-09-13 | — | — | WO | claimed |
| EP-1116716-A1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | Eisai Co., Ltd. (JP) | 2001-07-18 | — | — | EP | claimed |
| EP-0742207-A1 | 2-(Indan-1-one-2-yl-alkyl)-1-phenylalkyl-piperidines and processes for their preparation | Eisai Co., Ltd. (JP) | 1996-11-13 | — | — | EP | claimed |
| EP-0673927-A1 | 4-[2-indanyl-1-one]alkylpiperidines as anticholinergic agents | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | claimed |
| US-5100901-A | Treatment of Alzheimer*s disease | EISAI CO., LTD. (JP) | 1992-03-31 | — | — | US | claimed |
| EP-0296560-A2 | 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease | Eisai Co., Ltd. (JP) | 1988-12-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ACHE, BCHE, CHRM4 | MAOA 43/4885MAOB 60/4885CYP2A6 1457/4885 |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | NOTCH3, NOTCH2, NOTCH4 | MAOA 1116/4885MAOB 1644/4885CYP2A6 2425/4885 |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | MAOA 1099/4885MAOB 1097/4885CYP2A6 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.